NCT00299728View on ClinicalTrials.gov

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 21, 2006

Primary Completion Date

October 10, 2006

Study Completion Date

January 10, 2014

Conditions
Tumors
Interventions
BIOLOGICAL

NY-ESO-1 Protein Vaccine

NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG

Trial Locations (2)

10016

NYU Clinical Cancer Center, New York

10032

NY Presbyterian- Columbia, New York

Sponsors
All Listed Sponsors
collaborator

NYU Langone Health

OTHER

lead

Ludwig Institute for Cancer Research

OTHER